|
|
|
|
Compugen Announces Positive Therapeutic Effects Of Novel Peptide In Animal Model Of Inflammatory Bowel Disease
Irritable-Bowel Syndrome News Main Category: Irritable-Bowel Syndrome email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: 5 (1 votes) Health Professional:...
|
|
|
IBS in Children
Irritable Bowel Syndrome in Children( ) IBS is a functional gastrointestinal disorder marked by abdominal pain or discomfort, bloating, and irregular bowel habits, such as diarrhea or constipation.Functional...
|
|
|
Clinical Trials Update: June 25, 2009
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch: Irritable Bowel Syndrome (IBS) If you have irritable bowel syndrome, you may qualify for this study.The research site is in Bristol, Tenn....
National Womens Health Information Center:
Jun 25 2009 6:29PM
Matching: irritable bowel
|
Find similar documents
|
|
|
|
Clinical Trials Update: June 24, 2009
(HealthDay News) -- Here are the latest clinical trials, courtesy of ClinicalConnection.com and CenterWatch: This study will evaluate a new osteoarthritis medication.To qualify, you must be 18 or older, have a diagnosis of arthritis in...
National Womens Health Information Center:
Jun 24 2009 6:26PM
Matching: irritable bowel
|
Find similar documents
|
|
|
|
Pharming gets Dutch govt grant to develop human lactoferrin for IBD
Biotech company Pharming Group NV (Pharming) has initiated a two-year Food & Nutrition Delta (FND) innovation project to further develop human lactoferrin (hLF) as a nutritional product to manage inflammatory bowel diseases (IBD)....
|
|
|
What Is Gastroenteritis? What Is Food Poisoning?
GastroIntestinal / Gastroenterology News Editor's Choice Main Category: GastroIntestinal / Gastroenterology Also Included In: Infectious Diseases / Bacteria / Viruses; Crohn's; Irritable-Bowel Syndrome email to a friend printer...
|
|
|
What Is Endoscopy? What Is An Endoscope?
An endoscopy involves examining the inside of a person's body using an endoscope.An endoscope is a medical device consisting of a long, thin, flexible (or rigid) tube which has a light and a video camera. Images of the inside of the...
|
|
|
A Very Low-Carbohydrate Diet Improves Symptoms and Quality of Life in Diarrhea-Predominant Irritable Bowel Syn
Use of Antiemetic Agents in Acute Gastroenteritis 3.2008 Exclusive SurveyEarnings: Good news for primary care income 4. A Very Low-Carbohydrate Diet Improves Symptoms and Quality of Life in Diarrhea-Predominant Irritable Bowel...
|
|
|
New Interactive Tools From ACG Aim to Bring Hope to Millions of IBS Patients Searching for Relief
IBS Signs and Symptoms Tracker Sheds Light on IBS Warning Signs; IBS Treatment Matrix Helps Patients Find Relief BETHESDA, Md., May 29 /PRNewswire-USNewswire/ -- To mark World Digestive Health Day, the American College of Gastroenterology ...
|
|
|
New Interactive Tools From ACG Aim to Bring Hope to Millions of IBS Patients Searching for Relief
IBS Signs and Symptoms Tracker Sheds Light on IBS Warning Signs; IBS Treatment Matrix Helps Patients Find Relief BETHESDA, Md., May 29 /PRNewswire-USNewswire/ -- To mark World Digestive Health Day, the American College of Gastroenterology ...
|
|
|
New Interactive Tools From ACG Aim to Bring Hope to Millions of IBS Patients Searching for Relief
IBS Signs and Symptoms Tracker Sheds Light on IBS Warning Signs; IBS Treatment Matrix Helps Patients Find Relief BETHESDA, Md., May 29 /PRNewswire-USNewswire/ -- To mark World Digestive Health Day, the American College of Gastroenterology ...
|
|
|
Exagen Launches New Diagnostic Assays for Bowel Disease at Digestive Disease Week Conference
Company signs partnership agreement with Clinical Reference Laboratory ALBUQUERQUE, N.M., May 28 /PRNewswire/ -- Exagen Diagnostics, Inc.today announced the availability of two new genomic blood tests to assist physicians with diagnosing ...
|
|
|
Synergy Pharmaceuticals To Present Phase I Volunteer Study On SP-304 Investigational Drug To Treat GastroIntes
Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB SGY PNews), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that clinical data from the Phase I healthy volunteer study of SP-304, a new member of a...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorder
- Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB SGY PNews), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that clinical data from the Phase I healthy volunteer study of SP-304, a new member of...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorder
NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB SGY PNews), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that clinical data from the Phase I healthy volunteer study...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorder
- Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB SGY PNews), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that clinical data from the Phase I healthy volunteer study of SP-304, a new member of...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorder
NEW YORK - (BUSINESS WIRE) - Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB The poster presentation entitled: 'A Randomized, Double-blind, Placebo-Controlled, Single-, Ascending-, Oral-Dose Safety, Tolerability and Pharmacokinetic Study of...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to
BusinessWire - Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB SGY PNews), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that clinical data from the Phase I healthy volunteer study of SP-304, a...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorder
Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB SGY PNews), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that clinical data from the Phase I healthy volunteer study of SP-304, a new member of a...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorder
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB SGY PNews), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that clinical data from the Phase I healthy volunteer study of...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorder
Data to be Presented at Digestive Disease Week 2009 Conference NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB SGY PNews), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorder
Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB The poster presentation entitled: A Randomized, Double-blind, Placebo-Controlled, Single-, Ascending-, Oral-Dose Safety, Tolerability and Pharmacokinetic Study of SP-304 in Healthy Adult Human...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on
Synergy Pharmaceuticals, Inc.(OTC BB: SGYP.OB The poster presentation entitled: A Randomized, Double-blind, Placebo-Controlled, Single-, Ascending-, Oral-Dose Safety, Tolerability and Pharmacokinetic Study of SP-304 in Healthy Adult Human...
|
|
|
Synergy Pharmaceuticals to Present Phase I Volunteer Study on SP-304 Investigational Drug to Treat GI Disorder
NEW YORK--(BUSINESS WIRE)-- (OTC BB: SGYP.OB The poster presentation entitled: A Randomized, Double-blind, Placebo-Controlled, Single-, Ascending-, Oral-Dose Safety, Tolerability and Pharmacokinetic Study of SP-304 in Healthy Adult Human...
|
|
|
Manhattan Research Releases Digital DTC Relevance Rankings, Revealing Which Condition Groups Are Most Likely t
-Acne, Restless Leg Syndrome, and Cancer Patients are Among the Top Condition Groups Shaping the Future of Digital DTC Marketing New York, April 8, 2009 - More than 60% of U.S.adults turn to the Internet as a decision support tool in...
|
